Alterity Therapeutics

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. Our goal is to modify the course of these diseases and improve quality of life. Our lead asset, ATH434, has the potential to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically to reduce α-synuclein pathology and preserve nerve cells by restoring normal iron balance in the brain. As an iron chaperone, it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 is currently being evaluated in a global Phase 2 clinical trial in patients with early-stage MSA. Alterity also has a broad drug discovery platform generating patentable chemical compounds to intercede in disease processes. Alterity has offices in Melbourne, Australia and San Francisco, USA.